Safeguard Scientifics, Inc. (SFE) |
| 0.455 -0.197 (-30.21%) 02-09 16:00 |
| Open: | 0.65 |
| High: | 0.685 |
| Low: | 0.4004 |
| Volume: | 899,343 |
| Market Cap: | 8(M) |
| PE Ratio: | -0.72 |
| Exchange: | New York Stock Exchange |
| Industry: | Asset Management |
| Sector: | Financial Services |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 32.36 |
| Resistance 1: | 31.34 |
| Pivot price: | 30.67 |
| Support 1: | 29.68 |
| Support 2: | 24.69 |
| 52w High: | 3.25 |
| 52w Low: | 0.4 |
Safeguard Scientifics, Inc., while no longer actively pursuing new investments, previously functioned as a private equity and venture capital firm. It specialized in diverse funding approaches, including expansion financings, growth capital, management buyouts, recapitalizations, industry consolidations, corporate spinouts, and both growth-stage and early-stage investments. Initial investments typically targeted Series A through C funding rounds, with opportunistic engagement in seed-stage opportunities. The firm primarily directed its capital towards companies in the technology, financial services, and healthcare sectors. Within technology, its interests encompassed Software-as-a-Service (SaaS), adtech/digital media, the Internet of Everything (IoE), advanced security solutions, predictive analytics, machine learning, artificial intelligence, enterprise software, technology-enabled services, internet/new media, financial technology (fintech), cloud computing, mobile applications, social platforms, big data, in-memory computing, and select business services, often requiring up to $25 million in capital. In healthcare, Safeguard Scientifics backed ventures in molecular and point-of-care diagnostics, medical devices, regenerative medicine, broader medical technology, digital health, healthcare technology, specialty pharmaceuticals, and certain healthcare service providers. Geographically, the firm invested across the entire United States, with a particular focus on the Mid-Atlantic region, and also extended its reach to Southeastern Canada. Its typical investment sizes ranged from $5 million to $25 million for growth equity rounds, and between $5 million and $10 million for early-stage financing. Safeguard Scientifics commonly provided capital to a diverse array of entities, ranging from owner-financed or bootstrapped enterprises and corporate divisions to venture capital-backed companies seeking a strategic growth partner. Ideally, the firm aimed to be the largest shareholder in its portfolio companies, typically securing an ownership stake between 20% and 50%, although it occasionally took either a majority or a smaller position. A strong preference was given to companies leveraging proprietary technology and intellectual property. Furthermore, the firm generally pursued a board seat in its funded companies. Established in 1953 as Lancaster Corporation, the company officially adopted the name Safeguard Scientifics, Inc. in 1981. Its main office is situated in Radnor, Pennsylvania, complemented by an additional location in Weston, Massachusetts.
| EPS | 0.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | 0.0 |
| Return on Equity (ttm) | 0.0 |
Thu, 08 Sep 2022
Rockwell Medical Appoints Heather Hunter SVP - citybiz
Wed, 02 Dec 2020
Safeguard Scientifics Stock Price Forecast. Should You Buy SFE? - StockInvest.us
Sat, 19 May 2018
2018 Hall of Fame – Brad D. Smith Schools of Business - Marshall University
Wed, 17 Jan 2018
Safeguard Scientifics Announces Change in Strategy and Operations - PR Newswire
Tue, 06 Jun 2017
Trice Medical Closes $19.3 Million Series C Financing To Address Increased Demand For Mi-Eye - PR Newswire
Thu, 17 Nov 2016
T-REX Raises $10M Series B Financing To Enhance Liquidity In Structured Product Markets - PR Newswire
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |